Although trastuzumab, pertuzumab, plus docetaxel were found to extend overall survival (OS) among patients with HER2‐positive breast cancer as a first‐line therapy was observed in the CLEOPATRA study, only 11% of the study population had received trastuzumab.4 This evidence concerns the gene ERBB2 and breast carcinoma.